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Abstract
Background. Real-time collection of mental health and disease activity patient-reported outcomes (PROs) are
essential to assist clinicians in delivering optimal holistic health care. The aim of this pilot study was to validate
a digital support tool (DST) delivered via a tablet device in an outpatient setting to assess IBD activity and
psychological distress. Methods. 48 individuals (26 females; average age: 40.04) with IBD completed the
DST and a paper-based survey in a hospital IBD outpatient setting. PROs for disease activity and
psychological distress (Kessler K10) were compared to paper-based gold-standard measures of disease activity
(Partial Mayo Index or Harvey Bradshaw Index completed by the clinician) and psychological distress
(Depression Anxiety Stress Scale; completed by the patient). Patient feedback regarding usability and
acceptance of the DST was also collected. Results. DST patient-derived disease activity scores were
significantly correlated with clinician assessment of disease activity (p<0.01). Patient DST-derived
psychological well-being scores were also significantly correlated with the gold-standard measure of
psychological distress (p<0.05). Patients found the DST to be easy to use and identified a willingness to
follow through with the recommendations provided by the DST in relation to their psychological distress
scores. Conclusions. The pilot study demonstrates the value in collecting disease activity and psychological
distress PROs via a DST in an outpatient setting. Disease activity and psychological distress PROs were found
to correlate significantly with gold standard measures. The findings provide preliminary support for the value
of embedding digital technology into clinical care to promote patient engagement and optimal holistic
healthcare.
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Background. Real-time collection of mental health and disease activity patient-reported outcomes (PROs) are essential to assist
clinicians in delivering optimal holistic health care. The aim of this pilot study was to validate a digital support tool (DST)
delivered via a tablet device in an outpatient setting to assess IBD activity and psychological distress. Methods. 48 individuals (26
females; average age: 40.04) with IBD completed the DST and a paper-based survey in a hospital IBD outpatient setting. PROs
for disease activity and psychological distress (Kessler K10) were compared to paper-based gold-standard measures of disease
activity (Partial Mayo Index or Harvey Bradshaw Index completed by the clinician) and psychological distress (Depression
Anxiety Stress Scale; completed by the patient). Patient feedback regarding usability and acceptance of the DST was also
collected. Results. DST patient-derived disease activity scores were significantly correlated with clinician assessment of disease
activity (p < 0 01). Patient DST-derived psychological well-being scores were also significantly correlated with the gold-standard
measure of psychological distress (p < 0 05). Patients found the DST to be easy to use and identified a willingness to follow
through with the recommendations provided by the DST in relation to their psychological distress scores. Conclusions. The pilot
study demonstrates the value in collecting disease activity and psychological distress PROs via a DST in an outpatient setting.
Disease activity and psychological distress PROs were found to correlate significantly with gold standard measures. The findings
provide preliminary support for the value of embedding digital technology into clinical care to promote patient engagement and
optimal holistic healthcare.
1. Introduction
Recently within the inflammatory bowel disease (IBD) litera-
ture, an emphasis has been on the development and valida-
tion of patient-reported outcomes (PROs) [1, 2]. PROs
provide researchers and clinicians with a validated collection
of assessment tools which can be utilised in research trials
and in general patient settings. The goal of such PROs is to
assess multiple aspects of health, including physical and
psychosocial outcomes derived from the patient [1]. To date,
several PROs have been investigated. For disease activity,
Jairath et al. [3] developed a 2-item-based PRO for ulcerative
colitis (UC), while Khanna et al. [4] proposed a 2- and 3-
item-based PRO for Crohn’s disease (CD). Other PROs
explored include disability [5], work productivity [6], anxi-
ety, depression, and quality of life [2, 7].
In terms of patient settings, outpatient services provide
an ideal opportunity to collect PROs. As recommended by
several researchers [1, 2, 7], PROs collected in outpatient set-
tings can provide clinicians with current and comprehensive
biopsychosocial assessments, in turn allowing for optimal
care, not only relating to physiological functioning but also
other essential areas such as psychological comorbidity. In
a recent systematic review, Mikocka-Walus and colleagues
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identified that up to 66% of IBD patients experience comor-
bid anxiety and/or depression [8]. Mental health issues have
also been identified to exacerbate IBD activity [9–11] and
increase the risk of disease flare-ups [10, 12–14]. Given the
strong interrelationship between IBD and psychological
comorbidity, and the growing evidence base identifying the
impact of mental health on IBD, multiple IBD peak bodies
have recommended standards of IBD care that include the
review of and access to mental health services [15, 16].
The collection of disease activity and mental health PROs
in an outpatient setting could provide real-time information
to clinicians to facilitate a holistic optimal care approach.
Consequently, we sought to develop a digital support tool
(DST) application (or “app”) which could be delivered via a
tablet device in an outpatient setting to assess both disease
activity and mental health PROs.
The IBD patient assessment program (IBDPaP) is an
android-based DST app developed by the senior author
(SK) as a brief, easy to use, and flexible platform to record
patient details. The DST collects a variety of biopsychosocial
markers of well-being, including disease activity and psycho-
social functioning. IBD symptom activity questions were
derived from the Crohn’s Disease Activity Index (CDAI)
[17] and the Mayo Index [18]. The widely used and validated
Kessler 10-item psychological distress scale (K10) [19] was
used as the DST psychological distress PRO. IBDPaP also
assesses patient suicidality (“do you consider hurting your-
self, others, or feel suicidal? Yes/no”), current engagement
with mental health services (“are you currently seeing a
mental health professional? Yes/no”), and willingness to seek
help (“do you have an appointment with a mental health
expert within the next 14 days or are you willing to contact
your local doctor (GP) if your mental health symptoms
worsen?”). After completing the IBDPaP, patients are pro-
vided with feedback about mental health status. Summary
reports can then be either emailed in PDF format to the
patient’s gastroenterologist or printed via a cloud device.
The aim of this pilot study was to validate a DST app
delivered via a tablet device to assess patient-reported out-
comes (PROs) for IBD activity and psychological distress. It
was hypothesised that tablet-derived self-reported (1) disease
activity PRO for UC (SR-PRO2-UC) [3] would significantly
correlate with clinician verified partial Mayo Score [18] and
PRO2 (PRO2-UC); (2) disease activity PROs for CD
(SR-PRO2-CD and SR-PRO3-CD) [4] would significantly
correlate with clinician-verified Harvey Bradshaw Index
[20] and 2- and 3-item-based PRO for CD (PRO2-CD and
PRO3-CD); (3) psychological distress (K10) would correlate
significantly with a validated paper-based distress score
(Depression Anxiety Stress Scale; DASS); and (4) patient
feedback regarding mental health recommendations and
app-based usability and usefulness would be positive.
2. Materials and Methods
2.1. Patients. Eighty-one participants (47 female, mean age
38.28, SD = 14 76; 48 with Crohn’s disease) from an IBD out-
patient service completed a DST. From the initial 81 par-
ticipants, 48 (26 female, mean age 40.04. SD = 15 38; 25
with Crohn’s disease; average number of years diagnosed
9.62) also completed a paper-based survey. One patient
had a diagnosis of indeterminate colitis and was excluded
from the analysis.
2.2. Measures
2.2.1. Paper-Based Measures
(1) Modified Harvey-Bradshaw Index (MHBI). The Harvey-
Bradshaw Index (HBI) [20] is an efficient way to assess dis-
ease activity in CD patients. Respondents score 5 items
based on how they felt the previous day. Items include gen-
eral well-being, abdominal pain, number of liquid or soft
stools per day, abdominal mass, and additional manifesta-
tions. In the present study, however, the modified HBI
(MHBI) was used due to its improved simplicity and func-
tionality. The MHBI is identical to the HBI, except that the
question on abdominal mass is omitted, removing the need
for physical examination of the patient. The MHBI has also
been utilised in other cross-sectional studies with CD
patients [21, 22]. Higher scores on the MHBI indicate
greater disease severity, with scores equal to or below 5
indicating clinical remission.
(2) Patient-Reported Outcome for Crohn’s Disease (PRO2-CD
and PRO3-CD). The 2- and 3-item PRO for CD (PRO2-CD
and PRO3-CD, respectively) was based on items taken from
the MHBI as described by Khanna et al. [4]: loose bowel
movements [number of liquid or very soft stools] (×2),
abdominal pain [0 = none, 1 =mild, 2 =moderate, 3 =
severe] (×5), and for the third item, general well-being
[0 = very well, 1 = slightly below par, 2 = poor, 3 = very poor,
4 = terrible] (×7). Higher scores indicated greater disease
activity. For the 2-item PRO CD, remission was defined as
a mean daily stool frequency ≤ 1 5 and abdominal pain
score ≤ 1. For the 3-item PRO CD, the additional criterion
for remission was a general well-being score of ≤1.
(3) Partial Mayo Index (PMI). The Mayo Index [18] is a pop-
ular measure of ulcerative colitis disease activity. It includes
stool frequency, rectal bleeding, mucosal appearance, and
physician rating of disease activity. However, research sug-
gests that the inclusion of endoscopic components, such as
mucosal appearance, does not significantly contribute to the
predictive value of the index [23]. Thus, in the current study,
the noninvasive Partial Mayo Index (PMI) was used. All
items are scored from 0 to 3, with the total being out of 9;
scores equal to or below 1 indicate remission.
(4) Patient-Reported Outcome for Ulcerative Colitis (PRO2-
UC). The PRO2-UC was based on two items from the PMI
as described by Jairath et al. [3]: stool frequency (normal
[+0], 1-2 stools/day more than normal [+1], 3-4 stools/day
more than normal [+2], >4/day more than normal [+3]) and
rectal bleeding (none [+0], visible blood with stool less than
half the time [+1], visible blood with stool half of the time or
more [+2], passing blood alone [+3]). Remission was defined
as rectal bleeding = 0 and absolute stool frequency ≤ 2.
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(5) Short Form of the Depression Anxiety Stress Scales
(DASS21). The DASS21 is a validated measure of psycho-
logical distress [24, 25]. The scale consists of 21 state-
ments, which assess individual distress in the domains of
depression, anxiety, and stress. Respondents rate how
much each statement applied to them over the past week,
using a 4-point Likert scale, ranging from zero (did not
apply to me at all) to three (applied to me very much or
most of the time). A total distress scale score (0–126) is
derived by summing the items and multiplying by 2
[26]. Higher scores indicate greater distress in the corre-
sponding domains.
2.2.2. DST-Based Measures
(1) Disease Activity—Patient-Reported Outcomes (PROs).
Similar to the paper-based UC PROs, the items for the
SR-PRO2-UC were primarily based on the PMI. However,
slight modifications based on gastroenterologist feedback
were made to ensure patients were able to answer the ques-
tions most accurately and objectively. Based on these modifi-
cations, the 2-item disease activity score [3] was created
(SR-PRO2-UC; how many bowel movements do you have
per day? (0-2 stools/day [+0], 3 stools/day [+1], 4 stools/day
more than normal [+2], >5 or more/day more than normal
[+3]) and rectal bleeding (rectal bleeding over the last week:
none [0], streaks of blood [+1], obvious blood [+2], mostly
blood [+3]), with higher scores indicating greater disease
activity. Remission was defined as rectal bleeding = 0 and
absolute stool frequency ≤ 2.
For CD patients, disease activity PRO scores [4] used HBI
but modified items based on gastroenterologist feedback. The
2- and 3-item disease activity PRO scores (SR-PRO2-CD
and SR-PRO3-CD) assessed bowel movements (how many
of your bowel movements are loose/watery stools per day?
[number of liquid or very soft stools] (×2)), abdominal
pain/cramping (have you experienced abdominal pain or
cramping over the last week? [0 = none, 1 = mild, 2 =
moderate, 3 = severe] (×5)), and for the third item, general
well-being over the last week [0 = very well, 1 = slightly
below par, 2 = poor, 3 = very poor, 4 = terrible] (×2), with
higher scores indicating greater disease activity. For the
2-item PRO CD, remission was defined as a mean daily
stool frequency ≤ 1 5 and abdominal pain score ≤ 1. For
the 3-item PRO CD, the additional criterion for remission
was a general well-being score of ≤1. See Figure 1 for
example IBD symptom activity questions presented in
the IBDPaP.
(2)Kessler PsychologicalDistress Scale (K10)–Patient-Reported
Outcome (PRO). The Kessler Psychological Distress Scale
(K10) [27] is a 10-item questionnaire, commonly used as an
indicator of mental health status. Respondents answer a series
ofquestions regarding theirmentalhealthexperiencesover the
past 30 days, using a 5-point Likert scale from one (none of the
time) to five (all of the time) (see Figure 2 for IBDPaP K10
screenshot). K10 scores between 10-15, 16-30, and 31-50were
identified with minimal, moderate, or severe psychological
distress, respectively.
(3) Suicidality. A single question, “do you consider hurting
yourself, others, or feel suicidal,” was also included into the
tablet-based survey as a means to alert the clinician to any
patients at heightened risk of self-harm or suicide. Patients
who answered “yes” to this question would subsequently
receive a feedback page which advised them to seek support
Yes
Over the past week have you taken any
antidiarrheal medication
No
None
Over the past week, my rectal bleeding has
been
Streaks of blood
Obvious blood
Mostly blood
Very well
General well-being over the last weekCondition
IBD Activity IBD Activity
Number of years diagnosed with IBD
In the past 3 months my IBD has been
Over the past week, how many bowel
movements have you had per day
Over the past week, how many of your
bowel movements have been loose/
watery stools per day
Next
Slightly below par
Poor
Very poor
Terrible
Figure 1: Example of IBD symptom activity questions presented in the IBDPaP and used in the calculation of disease activity PROs.
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and to talk with their doctor (see Figure 3). Additionally,
patients’ IBDPaP reports were emailed to their gastroenter-
ologists, which ensured that appropriate referrals to mental
health professionals could also be provided for patients
deemed to be at increased risk.
(4) Automatic Feedback and Recommendations Tablet-Based
Psychological Distress Screening. Based upon responses from
the K10 and suicidality question, patients were presented
with automatically generated feedback and recommenda-
tions (see Figure 3). If respondents identified any suicidality,
During the last 30 days, about often did
you feel tired out for not good reason?
During the last 30 days, about often did
you feel so restless you could not sit still?
Mental Health ReviewMental Health Review
During the last 30 days, about often did
you feel depressed?
During the last 30 days, about often did
you feel that everything was an effort?
During the last 30 days, about often did
you feel so sad that nothing could cheer
you up?
During the last 30 days, about often did
you feel worthless?
During the last 30 days, about often did
you feel nervous?
During the last 30 days, about often did
you feel so nervous that nothing could
calm you down
During the last 30 days, about often did
you feel hopeless?
During the last 30 days, about often did
you feel restless or fidgety?
NextPreviousNextPrevious
Figure 2: IBDPaP K10 screenshot.
If you have any questions or concerns please
talk to your mental health professional
If you have any questions or concerns please
talk to your mental health professional
We recommend you meet with your mental
health professional if symptoms worsen. For
further information and strategies to manage
psychological distress please go to
Individuals tend to report some symptoms
which may be associated with psychological
distress. These symptoms may be causing
some distress in your life.
Unless you are doing so already, we
recommend you contact your mental health
professional or doctor as soon as possible to
arrange a mental health review.
Individuals tend to report strong and frequent
symptoms which may be associated with
psychological distress
Are you considering
harming yourself
or thinking about
suicide? Saving
Lives
13 11 14
Lifeline.org.au
Crisis Chat
(Available every night)(24/7)
Crisis Support Suicide PreventionPlease talk about
these thoughts/
feelings with
yourhealth
professional or
doctor.
Please review these results with your mental
health professional.
http://www.beyondblue.org.au/
Depression Anxiety
Depression Anxiety
http://www.beyondblue.org.au/
Mental Health Status
For further information and strategies to
manage psychological distress related to:
Individuals tend to report minimal levels of
psychological distress
Mental Health Status Mental Health Status
Next
Next
Next
Figure 3: Mental health feedback responses, delivered dependent on the reported levels of psychological distress from low (left) and moderate
(middle) to severe (right).
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they were provided with the same feedback provided to the
severe K10 distress category.
(5) DST Experience. Eight questions assessed patient opinions
and experiences in relation to using the DST (e.g., “how easy
was it to use this tablet-based program?”) and receiving the
automated feedback (e.g., “how helpful was this advice?”
and “how likely are you to follow up on the advice that was
provided?”), as well as the perceived benefit of integrating
the DST into their ongoing care (e.g., “do you feel the infor-
mation collected in this tablet-based program will help you
and your gastroenterologist better manage your IBD in a col-
laborative way?” and “do you feel more motivated to manage
your IBD after completing this tablet-based program?”).
Questions were assessed on a 10-point Likert scale, e.g., 0 =
“not at all” to 10 = “very much so.”
2.3. Procedure. Patients were approached at the IBD outpa-
tient service. Consenting participants completed the IBDPaP
DST on a Samsung 8” tablet and were then provided with a
paper-based questionnaire. Patients could choose to com-
plete the questionnaire while waiting for their appointment
or complete at home within 24 hours and mail back using
the prestamped and addressed envelopes. During the outpa-
tient appointment, the clinician completed the patient’s dis-
ease activity measures (i.e., PMI or HBI) in the paper-based
questionnaire. Ethical approval was attained from the local
university and hospital ethics committees prior to commenc-
ing the study.
2.4. Data Analyses. Analyses were conducted using IBM SPSS
version 21. To allow for combined analysis of IBD disease
activity across both CD and UC patients, the MHBI and
PMI scores were first converted into Z-scores. Chi-square
and t-tests were used to examine potential differences in
demographic and psychometric variables between those
who did and did not complete the paper-based questionnaire.
Correlation analyses were performed to determine whether
the tablet-derived disease activity PROs were associated with
clinician-verified indices and paper-based PROs. Addition-
ally, the correlation analysis examined whether the tablet-
based psychological distress (K10) PRO was associated with
the paper-based DASS21. Given that the assumption of nor-
mality was violated for several of the variables, Spearman’s
rho was utilised for all correlational analyses. Descriptive sta-
tistics on patients’ experiences with the tablet-based survey
were also explored.
3. Results
There were no significant differences in age, gender, or
disease type and severity between those who did and did
not complete the paper-based surveys. Similarly, there were
no significant differences in psychological distress between
these two groups. Of the 47 CD and UC patients who com-
pleted both the tablet- and paper-based surveys, the K10
scores identified 15 responders (31.9%) to be experiencing
minimal psychological distress, while 27 (57.4%) had moder-
ate psychological distress and 5 (10.6%) indicated severe
psychological distress. Five participants (10.4%) identified
positively to suicidal ideation and either not having an
appointment with a mental health expert within the next 14
days or willing to contact their local doctor (GP) if their men-
tal health symptoms worsen. All 5 participants were subse-
quently assessed during the gastroenterology appointment
and provided an appropriate referral.
4. Relationships between Tablet- and
Paper-Based Measures of Disease Activity
and Psychological Distress
Prior to assessing relationships involving the disease activity
PROs, differences in item format between gastroenterologist
and patient self-completed disease activity items were evalu-
ated. A series of t-tests indicated that there were no signifi-
cant differences, suggesting similar responses by both
gastroenterologists and patients despite the slight wording
differences in items and response format.
There was consistency across each measure of disease
activity for both CD and UC, with all related disease activity
measures showing significant interrelations (see Table 1).
Specifically, the tablet-derived PROs for CD demonstrated
strong significant correlations with clinician-verified MHBI
scores and paper-based CD PROs. Likewise, the tablet-
derived PROs for UC were found to have a strong significant
correlation with the clinician-verified Partial Mayo Index and
the paper-based UC PRO although these correlations were
stronger when using clinician-derived PRO scores (e.g.
PRO2-CD) versus patient-derived PRO scores (e.g. PRO2-
CDSR). Patient scores on the tablet-derived K10 showed a
strong positive association with scores on the paper-based
DASS21. This demonstrates that psychological distress scores
were also consistent across tablet- and paper-based measures.
4.1. Accuracy of Remission Rates across Tablet- and Paper-
Based Disease Activity Measures. Table 2 shows there was a
strong overlap between the percentage of patients in remis-
sion across clinician-reported measures of disease activity
and PROs for both CD and UC. While the PROs typically
identified fewer patients as being in remission than the
clinician-reported measures, the percentage overlap was sim-
ilar between both the paper- and tablet-derived PROs.
4.2. Patient Perceptions of DST Experience. Examination of
descriptive statistics on patients’ experiences with the tablet-
based survey (see Figure 4) suggested thatmost patients found
the tablet easy to use (M = 7 51, SD = 1 02) and found it help-
ful (M = 6 54, SD = 1 89). Similarly, several patients felt moti-
vated to manage their IBD after completing the survey
(M = 5 46, SD = 2 13) and reported the information collected
to be helpful to both themselves and their gastroenterologist
in the management of their IBD (M = 5 98, SD = 2 07).
As shown in Figure 5, the results indicated that the
instant feedback and advice were often perceived to be help-
ful (M = 5 44, SD = 1 99) and consistent with patients’ sense
of mental health (M = 5 51, SD = 2 28). While fewer patients
reported that they would highly likely follow the advice given
(M = 4 71, SD = 2 05), patients did not typically report high
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levels of distress after receiving the feedback (M = 2 43,
SD = 1 85).
5. Discussion
Optimal management of a patient’s well-being requires the
collection of information in a timely and accurate way.
DSTs are increasingly being identified as an important
technology which can be embedded within traditional
healthcare practice to help facilitate the monitoring and
management of patient well-being. The current pilot study
aimed to validate the IBDPaP, a DST designed to be utilised
in IBD outpatient settings to (a) collect information regard-
ing disease activity and mental health and (b) provide recom-
mendations based upon participant mental health scores.
The results provided support for the first hypothesis that
the IBDPaP DST patient-reported disease activity PROs for
UC and CD significantly correlated with the clinician-
derived disease activity PROs. Further, exploration of disease
activity PROs dichotomised into either active or nonactive
Table 1: Spearman’s rho correlations and descriptive statistics of disease activity and psychological variables.
1 2 3 4 5 6 7 8 9 10 Mean (SD)
1. Standardizeddisease activity scores — 0.04 (1.00)
2. MHBI (paper) 1.00∗∗∗ — 3.52 (3.29)
3. PRO2-CD 0.95∗∗∗ 0.95∗∗∗ — 7.20 (6.17)
4. PRO3-CD 0.88∗∗∗ 0.88∗∗∗ 0.88∗∗∗ —
13.64
(12.20)
5. PRO2-CDSR (tablet) 0.81∗∗∗ 0.81∗∗∗ 0.82∗∗∗ 0.78∗∗∗ — 8.92 (10.92)
6. PRO3-CDSR (tablet) 0.79∗∗∗ 0.79∗∗∗ 0.78∗∗∗ 0.82∗∗∗ 0.96∗∗∗ —
15.92
(17.26)
7. Partial Mayo (paper) 0.99∗∗∗ — — — — — — 1.32 (2.08)
8. PRO2-UC 0.97∗∗∗ — — — — — 0.99∗∗∗ — 0.91 (1.11)
9. PRO2-UCSR (tablet) 0.56∗∗ — — — — — 0.55∗∗ 0.58∗∗ — 1.50 (1.54)
10. K10 (tablet) 0.45∗∗ 0.57∗ 0.57∗∗ 0.67∗∗ 0.60∗∗ 0.68∗∗∗ 0.17 0.22 0.43∗ — 20.17 (8.21)
11. DASS21 (paper) 0.30∗ 0.42∗ 0.35 0.40 0.38 0.40∗ 0.02 0.06 0.38 0.74∗∗∗
15.68
(13.79)
Note. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001.
Table 2: Percentage of patients in remission across both CD and UC measures and PROs.
Crohn’s disease Ulcerative colitis
Sample
(n)
Patients in
remission (%)
Correct overlap with
MHBI (%)
Sample
(n)
Patients in
remission (%)
Correct overlap with
PMI (%)
MHBI 25 80.0% — PMI 22 72.7% —
PRO2-CD 25 60.0% 80.0% PRO2-UC 22 90.9% 81.8%
PRO3-CD 25 52.0% 72.0% PRO2UCSR 22 59.1% 77.3%
PRO2CDSR 25 48.0% 68.0%
PRO3CDSR 25 48.0% 68.0%
1 2 3 4 5 6 7 8
How easy was it to use this tablet-based program?
How helpful was it to use this tablet based
program?
Do you feel that the information collected in this
tablet-based program will help you and your
gastroenterologist better manage your IBD in a…
Do you feel more motivated to manage your IBD
after completing this tablet-based program?
Figure 4: Patient perceptions on use of tablet-based program.
6 Gastroenterology Research and Practice
cases indicated that clinician-derived PROs could correctly
identify remission status (compared against clinician-
completed HMBI or PMI) in 72-80% of CD patients and
81.8% of UC patients. Likewise, consistency for patient-
derived PROs was not much lower, with remission status
identified correctly in 68% of CD patients and 77.3% of UC
patients. Interestingly, this demonstrates that while
clinician-derived PROs were understandably more accurate
in classifying active or nonactive cases, the patient-reported
PROs were correct in a high proportion of cases also. How-
ever, given that around 20% of cases are misclassified when
using clinician-derived PROs, further work on developing
these PROs is needed. Despite the identified limitations, the
results provide preliminary support for the use of a DST to
collect disease activity PROs. With further research, DSTs
could become highly valuable and efficacious in informing
clinicians about their patients’ current IBD symptoms, sever-
ity, and perceived illness status. The findings also provide
further evidence for the value of assessing PROs in outpatient
settings [1, 2, 7].
Supporting the study’s third and fourth hypotheses were
the findings that the IBDPaP DST patient-reported psycho-
logical distress score was significantly correlated with the
paper-based distress score (DASS21) and that patients per-
ceived the IBDPaP DST as easy to use and helpful, whilst
motivating them to better manage their symptoms. While
patients identified that the feedback from the DST based
upon their mental health scores was helpful, they reported
being less likely to follow up on the advice provided. Impor-
tantly, of the participants who completed the IBDPaP DST, 5
participants (10.4%) identified positively to suicidal ideation
and were subsequently assessed and referred appropriately.
The findings suggest that while IBDPaP DST was accurate
and helpful in collecting patient psychological distress status,
its recommendations provided were not necessarily going to
be followed up by patients. While these findings may reflect
the reluctance of patients with IBD to seek mental health sup-
port [28, 29], it was clear that the collection of this data was
helpful in identifying suicidality and informing clinicians
about their patients’ psychological well-being. The findings
are also consistent with past research and recommended care
standards identifying the importance of assessing mental
health issues in IBD cohorts [8, 15, 16].
As identified above, an important finding from this pilot
study was that patients respond positively to app-based
usability and usefulness. Thus, while further research is
important to determine the efficacy of the IBDPaP in improv-
ing features of patient care, these findings provide evidence
that the integration of DST apps such as the IBDPaP can be
well-accepted by patients and therefore hold great potential
for improving patient and clinical management of IBD in
the future.
However, the current study is not without limitations.
While disease activity was assessed using validated measures,
it did not utilise the full-scale and unmodified versions which
include objective measures such as endoscopic information
and biomarkers such as faecal calprotectin. Future research
would benefit from utilising full-scale measures of disease
activity along with objective measures and biomarkers. While
it is essential that disease activity PROs are assessed, it is also
worth noting that at this time, research validating such PROs
is limited. Further, our study identified that the overlap
between these PROs and standardised measures was low
(e.g., 68% overlap for self-report CD PROs and MHBI).
Clearly, further research is needed to develop well-validated
and accurate disease activity PROs. In relation to patient
completed PROs (PRO2CDSR, PRO3CDSR, and PRO2
UCSR), due to the DST not differentiating between disease
type, it instead asked the same disease-related questions.
Consequently, to reduce patient question fatigue and
improve patient understanding, a reduced number and com-
bination of HBI and PMI items were used. Further research is
needed to validate format and type of questions used to assess
disease activity PROs as completed by patients using such
tools as the DST. The study also did not assess the perceived
utility of the IBDPaP DST as perceived by clinicians. Anec-
dotal feedback from clinicians was that the IBDPaP DST
was easy to implement in the service, useful in helping to
inform patient disease management plans, and provided a
way to identify and explore patient perceptions relating to
their physical and mental health. Future research should for-
mally assess the perceptions of patients and clinicians in rela-
tion to the value of the IBDPaP DST in IBD outpatient
settings. Future research could also explore the potential util-
ity of adapting the DST to enable patients to provide disease
activity (including faecal calprotectin values) and mental
1 2 3 4 5 6 7 8
How helpful was this advice?
How likely are you to follow up on the advice
that was provided?
Did you experience any distress after receiving
feedback about your results?
Are the results provided consistent with your
sense of current mental health status?
Figure 5: Patient perceptions on mental health feedback.
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health symptoms on a regular basis at home along with data
collection during an outpatient appointment. Finally, while
the pilot study provides promising results, future research
should be undertaken using a larger sample size stratified
by disease class, gender, and age to evaluate the temporal reli-
ability of the IBDPaP DST.
6. Conclusion
In the age of “apps” and patient empowerment, integrating
DSTs to assess PROs prior to clinic visits will assist both
patients and clinicians in focusing on what is important.
Despite the small sample size, the study demonstrated
strong correlations between IBDPaP DST patient-derived
disease activity PROs and clinician-derived disease activity
scores, as well as between patient-derived mental health
PROs and a gold standard mental health measure. Further,
the IBDPaP DST was able to alert clinicians to suicidal ide-
ation in patients. An important finding from this pilot study
was that patients found the IBDPaP DST to be beneficial,
easy to use, and it was perceived that the app would assist
patients and their gastroenterologists to better manage IBD
in a collaborative way. Our study suggests that the IBDPaP
is well received by patients and therefore presents a feasible
approach for the facilitation of patient engagement and opti-
mal holistic healthcare.
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